Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP System in patients with pollen‐related allergy to birch and apple
Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP System in patients with pollen‐related allergy to birch and apple
复制标题
通过 Pharmacia CAP 系统对重组过敏原 Bet v 1 和 Bet v 2 (profilin) 对桦树和苹果花粉相关过敏的患者进行评估
DOI：
10.1111/j.1398-9995.1996.tb04498.x
复制
发表时间：
1996
期刊：
影响因子：
12.4
通讯作者：
M. Corsi
中科院分区：
文献类型：
--
作者：
R. Rossi;G. Monasterolo;D. Operti;M. Corsi
用Pharmacia CAP系统对65例表现为鼻结膜炎或哮喘的患者进行了研究，以评估重要的桦树花粉变应原Bet v 1和Bet v 2的特异性IgE。所有65名受试者对至少一种重组桦树过敏原有反应：对Bet v 1有43%，对Bet v 2有30.7%，对两者都有26%。有口腔过敏综合征史的患者中，16/28例(57%)对Bet v1有反应；20例多敏受试者中，4例对Bet v2有反应(20%)。在抗这两种重组变应原的IgE患者中，有6人(35.30%)在吃苹果后出现过敏症状。我们的结果表明，对Bet v1的敏化是桦树和苹果过敏的特异性，而对Bet v2的敏化在多敏化患者中是常见的。
Sixty‐five patients presenting either rhinoconjunctivitis or asthma and sensitized to pollens of trees of the order Fagales were studied by the Pharmacia CAP system in order to assess specific IgE for the important birch pollen allergens Bet v 1 and Bet v 2. All 65 subjects reacted to at least one of the recombinant birch allergens: 43% to Bet v 1, 30.7% to Bet v 2, and 26% to both. Patients monosensitized to birch did not react to Bet v 2. Of patients with a history of oral allergy syndrome after eating apples, 16/28 (57%) reacted to Bet v 1; among 20 polysensitized subjects presenting oral allergy syndrome after consumption of apple, four reacted to Bet v 2 (20%). Among patients with IgE against both recombinant allergens, six (35.30%) presented symptoms of allergy after eating apples. Our results indicate that sensitization to Bet v 1 is specific for birch and apple allergies, whereas sensitization to Bet v 2 is common in polysensitized patients.